Cost per clinical outcomes with biologics for the treatment of moderately to severely active ulcerative colitis

被引：0
|
作者：
Jansen, J. [1 ]
Mody, R. [2 ]
Ursan, I. [2 ]
Lorenzi, M. [1 ]
Patel, H. [3 ]
Alberton, M. [1 ]
机构：
[1] Redwood Outcomes, San Francisco, CA USA
[2] Takeda Pharmaceut Int Inc, Global Outcomes Res, Deerfield, IL USA
[3] Immens Consulting Inc, Chicago, IL USA
来源：
JOURNAL OF CROHNS & COLITIS | 2015年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P322
引用
收藏
页码：S239 / S240
页数：2
相关论文
共 50 条
  • [1] Cost Per Clinical Outcomes With Biologics for the Treatment of Moderately to Severely Active Ulcerative Colitis
    Jansen, Jeroen P.
    Mody, Reema
    Patel, Haridarshan
    Lorenzi, Maria
    Ursan, Iulia
    Alberton, Mark
    [J]. GASTROENTEROLOGY, 2015, 148 (04) : S1 - S2
  • [2] Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis
    Toor, Kabirraaj
    Druyts, Eric
    Jansen, Jeroen P.
    Thorlund, Kristian
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (06) : 437 - 446
  • [3] Vedolizumab for the Treatment of Moderately to Severely Active Ulcerative Colitis
    Dulai, Parambir S.
    Mosli, Mahmoud
    Khanna, Reena
    Levesque, Barrett G.
    Sandborn, William J.
    Feagan, Brian G.
    [J]. PHARMACOTHERAPY, 2015, 35 (04): : 412 - 423
  • [4] Cost-Effectiveness of Vedolizumab Compared With Conventional Therapy and Biologics for Treatment of Moderately to Severely Active Ulcerative Colitis in the United States
    Wilson, Michele
    Mody, Reema
    Ursan, Iulia
    Carr, Sean
    [J]. GASTROENTEROLOGY, 2015, 148 (04) : S198 - S199
  • [5] COST-EFFECTIVENESS OF ADALIMUMAB FOR THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN CANADA
    Ghosh, S.
    Desjardins, O.
    Skup, M.
    Wang, S.
    Yang, M.
    Yang, H.
    Qi, C.
    Bao, Y.
    Chao, J.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A37 - A37
  • [6] Cost-Effectiveness of Adalimumab in Moderately to Severely Active Ulcerative Colitis
    Ali, Tauseef
    Skup, Martha
    Yang, Mei
    Yang, Min
    Wu, Eric
    Mulani, Parvez
    Chao, Jingdong
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S641 - S641
  • [7] Golimumab for moderately to severely active ulcerative colitis
    Kedia, Saurabh
    Ahuja, Vineet
    Makharia, Govind K.
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (10) : 1273 - 1282
  • [8] Filgotinib for moderately to severely active ulcerative colitis
    Mannucci, Alessandro
    D'Amico, Ferdinando
    El Saadi, Ahmad
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    [J]. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 16 (10) : 927 - 940
  • [9] Adalimumab for Induction of Clinical Remission in Moderately to Severely Active Ulcerative Colitis
    Reinisch, Walter
    Sandborn, William J.
    Hommes, Daniel W.
    D'Haens, Geert R.
    Hanauer, Stephen B.
    Schreiber, Stefan
    Panaccione, Remo
    Fedorak, Richard N.
    Tighe, Mary Beth
    Huang, Bidan
    Lazar, Andreas
    [J]. GASTROENTEROLOGY, 2010, 138 (05) : S114 - S115
  • [10] Understanding the Role of Adalimumab in the Treatment of Moderately to Severely Active Ulcerative Colitis
    Kim, Jae Hyun
    Cheon, Jae Hee
    [J]. GUT AND LIVER, 2016, 10 (02) : 162 - 163
12345